REFERENCES
1. Celsa C, Cabibbo G, Fulgenzi CAM, et al. Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: the impact of successful antiviral treatment. Hepatology. 2025;81:837-52.
2. Rabasco Meneghetti A, Campani C, Roux C, et al. Detection of esophageal varices and prediction of hepatic decompensation in unresectable hepatocellular carcinoma using AI. J Hepatol. 2026;84:1149-63.
3. Blankemeier L, Kumar A, Cohen JP, et al. Merlin: a computed tomography vision-language foundation model and dataset. Nature. 2026;652:1318-28.
4. Vithayathil M, Koku D, Campani C, et al. Machine learning based radiomic models outperform clinical biomarkers in predicting outcomes after immunotherapy for hepatocellular carcinoma. J Hepatol. 2025;83:959-70.
5. Xia Y, Zhou J, Xun X, et al. CT-based multimodal deep learning for non-invasive overall survival prediction in advanced hepatocellular carcinoma patients treated with immunotherapy. Insights Imaging. 2024;15:214.
6. de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C; Baveno VII Faculty. Baveno VII - renewing consensus in portal hypertension. J Hepatol. 2022;76:959-74.
7. Villanueva C, Albillos A, Genescà J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2019;393:1597-608.
8. Thabut D, Kudo M. Treatment of portal hypertension in patients with HCC in the era of Baveno VII. J Hepatol. 2023;78:658-62.
9. Allaire M, Campion B, Demory A, et al. Baveno VI and VII criteria are not suitable for screening for large varices or clinically significant portal hypertension in patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2023;58:346-56.
10. Baveno VIII Faculty. Baveno VIII - advancing consensus in portal hypertension. J Hepatol. 2026;85:993-1018.
11. Wu CW, Lui RN, Wong VW, et al. Baveno VII criteria is an accurate risk stratification tool to predict high-risk varices requiring intervention and hepatic events in patients with advanced hepatocellular carcinoma. Cancers. 2023;15:2480.
12. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310-35.
13. Kramer G, Hildeman A, Tozzi C, et al. A machine learning approach to non-invasive prediction of hepatic decompensation in compensated advanced chronic liver disease: the CIRI model. J Hepatol. 2026;Epub ahead of print.
14. Collins GS, Moons KGM, Dhiman P, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378.
